2017 Archive

ClinDatrix provided full service for the successful Phase 3 study of the following contact lens solution for Bausch + Lomb:

Bausch + Lomb Introduces renuĀ® Advanced Formula Multi-Purpose Solution

ClinDatrix provided full service for the Phase 2 and Phase 3 studies leading to the approval of Endari, an orphan drug for sickle cell disease for Emmaus Medical:

FDA approves new treatment for sickle cell disease